Open AccessClinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy
Author(s) -
Gemma Bruera,
Antonio Russo,
Sérgio Rizzo,
Enrico Ricevuto
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.14333
Subject(s) - medicine , bevacizumab , mucositis , colorectal cancer , oncology , neutropenia , cancer , chemotherapy
Bevacizumab addiction to triplet chemotherapy, according to FIr-B/FOx schedule, as first-line treatment in young-elderly metastatic colorectal CANCER (MCRC) patients may be more effective. Tailored treatments show worse clinical outcome in unfit patients.